Table 5.
Mortality by species and initial antifungal treatment for the 278 patients receiving antifungal treatment
| Species (n) | Overall % mortality | No. of deaths/no. of treated patients (% mortality) with initial antifungal compound |
P value | |||
|---|---|---|---|---|---|---|
| Amphotericin deoxycholate or lipid formulation | Caspofungin | Fluconazole | Voriconazole | |||
| C. krusei (22) | 36 | 1/4 | 5/10 (50) | 0/3 | 2/5 | |
| C. tropicalis (15) | 33 | 1/5 | 1/3 | 3/7 | 0/0 | |
| C. glabrata (58) | 32 | 4/13 (31) | 2/17 (12) | 13/27 (48) | 0/1 | 0.023a |
| C. albicansb (154) | 28 | 7/20 (35) | 6/28 (21) | 30/104 (29) | 0/2 | 0.34c |
| C. parapsilosis (15) | 25 | 0/4 | 0/2 | 3/9 (33) | 0/0 | |
| Candida spp. (9) | 14 | 0/2 | 0/1 | 1/6 | 0/0 | |
| Other fungi (5) | 17 | 0/0 | 1/2 | 0/3 | 0/0 | |
| Total (278) | 29 | 13/48 (27) | 15/63 (24) | 50/159 (31) | 2/8 | 0.327d |
a
Comparing mortality rates for patients with C. glabrata receiving caspofungin or fluconazole as the first antifungal compound.
b
Figures are for C. albicans (148 isolates) and C. dubliniensis (6 isolates).
c
Comparing mortality rates for patients with C. albicans receiving caspofungin or amphotericin B as the first antifungal compound.
d
Comparing mortality rates for all patients receiving caspofungin or fluconazole as the first antifungal compound.